Zacks Investment Research
03 Sept 2026, 22:46 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Viking Therapeutics is anticipated to report a quarterly EPS of -$1, representing a 23.46% decline compared to the same quarter last year. — A significant year-over-year drop in earnings per share typically signals deteriorating financial health or increased costs, which is negative for share price.
-0.40Zacks Consensus Estimates predict full-fiscal year earnings of -$4.47 per share, a decrease of 40.13% from the previous year. — A steep decline in annual earnings expectations suggests a negative long-term profitability trend for the company.
-0.30The Medical - Biomedical and Genetics industry is ranked in the bottom 34% of all Zacks-tracked industries. — Weak industry-wide ranking suggests systemic headwinds for companies within this specific sector.
-0.20Continue reading
6 related stories
Top 3 movers · tap to explore
Viking Therapeutics currently holds a Zacks Rank of #3 (Hold). — A 'Hold' rating indicates neutral sentiment and suggests the stock is expected to perform in line with the broader market.
+0.00Which stocks this story touches
The company is expected to report a significant fall in EPS compared to the previous year and is currently ranked as a 'Hold'.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
1h ago
